EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis

Jehad Barakji iD, Steven Kwasi Korang, Joshua Feinberg iD, Mathias Maagaard, Ole Mathiesen iD, Christian Gluud, Janus Christian Jakobsen

PLOS ONE · 30.01.2023 · 18 (1) · e0267420

DOI: 10.1371/journal.pone.0267420 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 30.01.2023. Verfasst von Jehad Barakji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital ─ Rigshospitalet, Copenhagen, De…. Hauptthemen laut MEDLINE: Acute Pain, Cancer Pain, Chronic Pain, Cannabinoids. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grosserer A.V. Lykfeldt og Hustrus Legat.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the benefits and harms of cannabinoids in participants with pain.

Design

Systematic review of randomised clinical trials with meta-analysis, Trial Sequential Analysis, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Data sources The Cochrane Library, MEDLINE, Embase, Science Citation Index, and BIOSIS. Eligibility criteria for selecting studies Published and unpublished randomised clinical trials comparing cannabinoids versus placebo in participants with any type of pain. Main outcome measures All-cause mortality, pain, adverse events, quality of life, cannabinoid dependence, psychosis, and quality of sleep.

Results

We included 65 randomised placebo-controlled clinical trials enrolling 7017 participants. Fifty-nine of the trials and all outcome results were at high risk of bias. Meta-analysis and Trial Sequential Analysis showed no evidence of a difference between cannabinoids versus placebo on all-cause mortality (RR 1.20; 98% CI 0.85 to 1.67; P = 0.22). Meta-analyses and Trial Sequential Analysis showed that cannabinoids neither reduced acute pain (mean difference numerical rating scale (NRS) 0.52; 98% CI -0.40 to 1.43; P = 0.19) or cancer pain (mean difference NRS -0.13; 98% CI -0.33 to 0.06; P = 0.1) nor improved quality of life (mean difference -1.38; 98% CI -11.81 to 9.04; P = 0.33). Meta-analyses and Trial Sequential Analysis showed that cannabinoids reduced chronic pain (mean difference NRS -0.43; 98% CI -0.72 to -0.15; P = 0.0004) and improved quality of sleep (mean difference -0.42; 95% CI -0.65 to -0.20; P = 0.0003). However, both effect sizes were below our predefined minimal important differences. Meta-analysis and Trial Sequential Analysis indicated that cannabinoids increased the risk of non-serious adverse events (RR 1.20; 95% CI 1.15 to 1.25; P < 0.001) but not serious adverse events (RR 1.18; 98% CI 0.95 to 1.45; P = 0.07). None of the included trials reported on cannabinoid dependence or psychosis.

Conclusions

Cannabinoids reduced chronic pain and improved quality of sleep, but the effect sizes are of questionable importance. Cannabinoids had no effects on acute pain or cancer pain and increased the risks of non-serious adverse events. The harmful effects of cannabinoids for pain seem to outweigh the potential benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute PainCancer PainChronic PainCannabinoidsAnalgesicsHumansQuality of LifeSleepSleep QualityPlacebos

Substanzen

CannabinoidsAnalgesicsPlacebos

Autor:innen und Institutionen

  • Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital ─ Rigshospitalet, Copenhagen, Denmark.
  • Medical Department, Cardiology Section, Holbaek University Hospital, Holbaek, Denmark.
  • Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.
  • Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
  • Department of Regional Health Research, The Faculty of Heath Sciences, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Jehad Barakji, Joshua Feinberg, Ole Mathiesen

Förderung

  • Grosserer A.V. Lykfeldt og Hustrus Legat

Zitieren

APA

Barakji, J., Korang, S. K., Feinberg, J., Maagaard, M., Mathiesen, O., Gluud, C., & Jakobsen, J. C. (2023). Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PLOS ONE, 18(1), e0267420. https://doi.org/10.1371/journal.pone.0267420

Vancouver

Barakji J, Korang SK, Feinberg J, Maagaard M, Mathiesen O, Gluud C, et al. Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PLOS ONE. 2023;18(1):e0267420. doi:10.1371/journal.pone.0267420

BibTeX
@article{Barakji2023,
  author = {Barakji, Jehad and Korang, Steven Kwasi and Feinberg, Joshua and Maagaard, Mathias and Mathiesen, Ole and Gluud, Christian and Jakobsen, Janus Christian},
  title = {Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {1},
  pages = {e0267420},
  doi = {10.1371/journal.pone.0267420}
}
Kostenlos starten →